ASBMR Webinar: Managing bone health in the setting of anti-estrogen therapy used to treat early stage breast cancer from an oncologist’s perspective

Speaker is Cathy Van Poznak, M.D.

1)Three educational objectives of the webinar
a.Review the indication for anti-estrogen therapy in early stage breast cancer
b.Review the risk of osteoporosis and fracture in the setting of adjuvant anti-estrogen therapy for breast cancer
c.Review interventions to mitigate the risks of osteoporosis and fracture associated with anti-estrogen therapy for early stage breast cancer

2)A short description of the webinar material
To address the objectives the webinar will present data from
a)The adjuvant clinical trials demonstrating the anticancer efficacy of adjuvant tamoxifen and the aromatase inhibitors. In addition, data from the EBCTCG meta-analysis may be presented
b)Clinical trials demonstrating the rates of bone loss / fracture with anti-estrogen therapy used for early stage breast cancer
c)The ASCO guideline addressing osteoporosis in cancer will be presented, along with other guidelines.

In this webinar, Dr. Van Poznak will help participants understand the frequency with which anti-estrogen therapies are used in early stage breast cancer, recognize the associated impact that these therapies may have on osteoporosis and fracture, and review the guidelines available to screen, prevent and treat osteoporosis in early stage breast cancer.